- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Trends in Patient Chemo Care Add Strain to Medicare
A federal policy shift has triggered a decline in patients receiving less-costly chemotherapy in physicians’ offices and a surge of those in more expensive hospital outpatient departments, according to a study released Monday. The trend, experts say, could have lasting effects on the quality of patient care, the existence of independent clinics and the future of Medicare.
Moran Co., a Washington-based healthcare research firm, confirmed that Medicare payments for fee-for-service hospital-based chemotherapy treatments have increased significantly while those for physicians’ offices have fallen.
According to the study, between 2005 and 2011 Medicare payments for chemotherapy administration in hospitals tripled to $300.9 million from $98.3 million, while payments for physician clinic chemotherapy administration dropped by 14.5 percent to $433.8 million from $507.5 million.
Read the full story here: http://bit.ly/14vD0YE
Source: Medill Reports Chicago
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
